Posts

Posted on

PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group

PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group

Data presented at the CHEST 2025 Annual Meeting highlight deupirfenidone’s differentiated profile and potential to address unmet needs across age groups

BOSTON–(BUSINESS WIRE)–
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announced the presentation of new analyses from the Phase 2b ELEVATE IPF trial of deupirfenidone (LYT-100) for the treatment of idiopathic pulmonary fibrosis (IPF). The data show that the favorable safety and efficacy profile of deupirfenidone was consistent across age groups, including in patients aged 75 years and older. These findings, presented at the American College of Chest Physicians (CHEST) 2025 Annual Meeting, suggest that deupirfenidone may address a key gap in the treatment of IPF, as older patients have historically been less likely to be treated, largely due to tolerability challenges.1,2 These data further reinforce deupirfenidone’s differentiated profile and support its potential to meaningfully improve care for this vulnerable population.

“These data are a welcome indication that age does not necessarily translate to a poorer treatment experience in IPF, which is generally a disease of older people,” said Tejaswini Kulkarni, MD, MPH, Associate Professor of Pulmonary, Allergy and Critical Care Medicine at the University of Alabama at Birmingham, who presented the data at CHEST 2025. “Older people with IPF have historically been undertreated and underrepresented in clinical trials because antifibrotic medications can be especially difficult to tolerate for this demographic. Demonstrating consistent safety and efficacy, particularly in this population, reinforces the differentiated profile of deupirfenidone and its potential to benefit a broad range of patients living with IPF.”

ELEVATE IPF was a randomized, double-blind, active- and placebo-controlled Phase 2b trial evaluating deupirfenidone 825 mg TID and deupirfenidone 550 mg TID compared to placebo and pirfenidone 801 mg TID in patients with IPF. This sub-analysis primarily focused on safety and tolerability in patients aged ≥75 years (n=91) compared with those aged <75 years (n=166), as tolerability challenges are a primary barrier to treatment in older populations. Treatment emergent adverse events, including gastrointestinal events, were similar for both age groups, indicating that older patients tolerated deupirfenidone comparably to younger patients. For example, the rates of nausea in patients aged ≥75 years vs. <75 years were 18.2% vs. 21.4% for deupirfenidone 825 mg TID; 14.3% vs. 18.2% for deupirfenidone 550 mg TID; 25.9% vs. 27.8% for pirfenidone 801 mg TID; and 9.5% vs. 6.8% for placebo. Efficacy also remained consistent with previously reported results, providing additional support for deupirfenidone’s differentiated profile in this patient population.

“Older patients represent a large and growing segment of the IPF population, yet they’ve historically been less likely to receive treatment due to concerns around tolerability,” said Camilla Graham, MD, MPH, Senior Vice President of Medical Affairs at PureTech. “These findings highlight deupirfenidone’s potential to be an attractive treatment option for a broader range of patients, including those who have often been underserved, while maintaining the strong efficacy profile demonstrated in the Phase 2b trial.”

About Deupirfenidone (LYT-100)

Deupirfenidone (LYT-100) is in development as a potential new standard of care for the treatment of idiopathic pulmonary fibrosis (IPF). It is a next generation antifibrotic and a deuterated form of pirfenidone, one of three FDA-approved therapies for IPF. The uptake and adherence to approved antifibrotics has historically been limited by a tradeoff between modest efficacy and tolerability, and only ~25% of people with IPF in the U.S. had ever received treatment as of 2019.3

Deupirfenidone may overcome these limitations. In the global Phase 2b ELEVATE IPF trial, deupirfenidone demonstrated the potential to stabilize lung function decline over at least 26 weeks as a monotherapy while maintaining a favorable safety and tolerability profile. Initial data from an ongoing open-label extension study suggest this effect may be sustained through at least 52 weeks. These findings support the potential for deupirfenidone to offer a meaningful advance for people living with this progressive and deadly disease. Beyond IPF, deupirfenidone may also address multiple underserved fibrotic conditions, including progressive fibrosing interstitial lung diseases.

About Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic pulmonary fibrosis (IPF) is a rare, progressive, and fatal lung disease characterized by irreversible scarring of lung tissue that leads to a steady decline in lung function. Median survival following diagnosis is estimated to be two to five years, and currently there is no cure.4

About Celea Therapeutics

Celea Therapeutics is dedicated to advancing transformative treatments for people with serious respiratory diseases. Drawn from the Latin word for “sky,” the name reflects the company’s mission to rise above the status quo and deliver therapies that change lives. The company’s lead program, deupirfenidone (LYT-100), is a Phase 3-ready therapeutic candidate with the potential to set a new standard of care for idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases.

Celea was founded by PureTech Health plc (Nasdaq: PRTC, LSE: PRTC), a biotherapeutics company dedicated to giving life to science. PureTech’s innovative R&D model drives the creation of Founded Entities like Celea, enabling the advancement of highly promising medicines to patients in a capital-efficient manner. For more information, please visit www.celeatx.com and www.puretechhealth.com.

About PureTech Health

PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this through a proven, capital-efficient R&D model focused on opportunities with validated pharmacology and untapped potential to address significant patient needs. This strategy has produced dozens of therapeutic candidates, including three that have received U.S. FDA approval. By identifying, shaping, and de-risking these high-conviction assets, and scaling them through dedicated structures backed by external capital, we accelerate their path to patients while creating sustainable value for shareholders.

For more information, visit www.puretechhealth.com or connect with us on X (formerly Twitter) @puretechh.

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements that relate to continued development of and regulatory interactions related to deupirfenidone, the potential of deupirfenidone in IPF and other indications, our expectations around our therapeutic candidates and approach towards addressing major diseases, our plans to advance our programs and deliver on our milestones, our future plans, prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption “Risk Factors” in our Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

______________________________

1 Qiu, Y., Zhu, J., Chopra, P., Elpers, B., Dieyi, C., Byrne, C., Tang, J., Wang, Y., Govindaraj, K., & Fischer, A. (2024). Real-world antifibrotic treatment patterns in patients with idiopathic pulmonary fibrosis: retrospective analyses of two large healthcare administrative databases in the United States. Therapeutic Advances in Respiratory Disease, 18. https://doi.org/10.1177/17534666241280704

2 Cilli, A., Ocal, N., Uzer, F., Coskun, F., Sevinc, C., Ursavas, A., Yıldız, P., Deniz, P. P., Demirci, N. Y., Ozbey, G., Yurttas, A., & Hanta, I. (2023). Elderly idiopathic pulmonary fibrosis patients remain on therapy despite higher incidence of adverse events and dose reductions. Respiratory Investigation, 61(4), 490–497. https://doi.org/10.1016/j.resinv.2023.04.007

3 Dempsey, T. M., Payne, S., Sangaralingham, L., Yao, X., Shah, N. D., & Limper, A. H. (2021). Adoption of the antifibrotic medications pirfenidone and nintedanib for patients with idiopathic pulmonary fibrosis. Annals of the American Thoracic Society, 18(7), 1121–1128.
4 Fisher, M., Nathan, S. D., Hill, C., Marshall, J., Dejonckheere, F., Thuresson, P., & Maher, T. M. (2017). Predicting life expectancy for pirfenidone in idiopathic pulmonary fibrosis. Journal of Managed Care & Specialty Pharmacy, 23(3-b Suppl), S17–S24. https://doi.org/10.18553/jmcp.2017.23.3-b.s17

 

PureTech

Public Relations

[email protected]

Investor Relations

[email protected]

UK/EU Media

Ben Atwell, Rob Winder

+44 (0) 20 3727 1000

[email protected]

US Media

Justin Chen

[email protected]

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Science Seniors Biotechnology Research Pharmaceutical Health Consumer Clinical Trials

MEDIA:

Logo
Logo
Posted on

Owlet Announces Pricing of Public Offering of Class A Common Stock

Owlet Announces Pricing of Public Offering of Class A Common Stock

LEHI, Utah–(BUSINESS WIRE)–
Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, today announced the pricing of an underwritten public offering of 4,196,000 shares of the Company’s Class A common stock (the “Offering”). The shares of Class A common stock are being sold at a public offering price of $7.15 per share, before underwriting discounts and commissions. All of the shares in the Offering are to be sold by the Company. The gross proceeds to Owlet from the Offering are expected to be approximately $30.0 million, before deducting underwriting discounts and commissions and other offering expenses. The Company has granted the underwriters of the Offering a 30-day option to purchase up to an additional 629,400 shares of Class A common stock at the public offering price less the underwriting discounts and commissions. The Offering is expected to close on or about October 23, 2025, subject to the satisfaction of customary closing conditions.

Owlet intends to use the net proceeds from the Offering to support continued commercialization and research and development, and for general corporate purposes.

William Blair and TD Cowen are acting as the joint bookrunners for the Offering. Craig-Hallum is acting as co-manager for the Offering.

The securities described above are being offered by Owlet pursuant to an effective shelf registration statement on Form S-3 (File No. 333-281556) that was previously filed with the U.S. Securities and Exchange Commission (the “SEC”) on August 14, 2024. The Offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement, copies of which may be obtained, when available, by request from: William Blair & Company, L.L.C., Attn: Prospectus Department, 150 North Riverside Plaza, Chicago, Illinois 60606, by telephone at 1-800-621-0687 or by email at: [email protected]; or TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Owlet, Inc.

Owlet’s digital health infant monitoring platform is transforming the journey of parenting. The Company (NYSE: OWLT) offers FDA-cleared medical and consumer pediatric wearables and an integrated HD visual and audio camera that provides real-time data and insights to parents who safeguard health, optimize wellness, and ensure peaceful sleep for their children.

Since 2012, over two million parents worldwide have used Owlet’s platform, contributing to one of the largest collections of consumer infant health and sleep data. The Company continues to develop software and digital data solutions to bridge the current healthcare gap between hospital and home and bring new insights to parents and caregivers globally. Owlet believes that every child deserves to live a long, happy, and healthy life.

Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including, without limitation, statements regarding the completion of the Offering, the expected gross proceeds of the Offering, the anticipated use of proceeds from the Offering and the potential exercise by the underwriters of an option to purchase additional shares, are forward-looking statements reflecting the current beliefs and expectations of Owlet’s management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements represent Owlet’s current expectations regarding future events and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those implied by the forward-looking statements. Among those risks and uncertainties are market conditions, including market interest rates, tariffs, the trading price and volatility of Owlet’s Class A common stock, the satisfaction of closing conditions related to the Offering, and risks relating to Owlet’s business, including those identified in the “Risk Factors” section of Owlet’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, in its subsequent Quarterly Reports on Form 10-Q and other filings with the SEC, as well as the preliminary prospectus supplement and accompanying prospectus relating to the Offering. The forward-looking statements included in this press release speak only as of the date of this press release, and Owlet does not undertake to update the statements included in this press release for subsequent developments, except as may be required by law.

Media Contact:

[email protected]

Investor Contact:

[email protected]

KEYWORDS: United States North America Utah

INDUSTRY KEYWORDS: Children Data Management Technology Health General Health Wearables/Mobile Technology Health Technology Audio/Video Consumer Hardware Parenting

MEDIA:

Logo
Logo
Posted on

Silicon Labs Unveils the Next Evolution of IoT Development with the Simplicity Ecosystem

PR Newswire

Developers gain faster, smarter workflows today – and AI-powered collaboration in 2026


AUSTIN, Texas
, Oct. 22, 2025 /PRNewswire/ — Silicon Labs (NASDAQ: SLAB), the leading innovator in low-power wireless, today announced the launch of the Simplicity Ecosystem, a next-generation suite of modular software tools with planned AI augmentation designed to transform embedded IoT development. Anchored by Simplicity Studio 6 and complemented by the emerging Simplicity AI SDK framework, the ecosystem unifies installation, configuration, debugging, and analysis into a single intelligent, developer-first environment that delivers automation and insight at every stage of product creation.

“The Simplicity Ecosystem represents a major step in making intelligent, context-aware development a reality,” said Manish Kothari, Senior Vice President of Software Development at Silicon Labs. “By integrating AI into every layer of our tools, we will give developers a platform that learns, adapts, and accelerates innovation across the entire IoT lifecycle.”

From Integrated Development Environment (IDE) to Ecosystem

For more than a decade, Simplicity Studio has helped engineers build connected devices with speed and reliability. The new Simplicity Ecosystem extends that legacy by breaking the toolchain into modular, interoperable components, each designed to fit seamlessly into modern workflows, whether GUI-based or automated. The Simplicity Ecosystem supports Silicon Labs Series 2 and Series 3 devices and major IoT standards, including Bluetooth LE, Zigbee, Thread, Matter, Wi-Fi, Wi-SUN, and Z-Wave.

Core tools include:

  • Simplicity Installer – A lightweight package manager enabling on-demand installation of SDKs, examples, and tools. Developers can install only what they need, reducing overhead and startup time.
  • VS Code and CLI Integration – Simplicity Studio 6 embraces VS Code as its primary IDE, offering a flexible environment with a Simplicity Studio extension. Studio 6 also features generation of a modern CMake & Ninja build environment, enabling robust CLI automations supporting a range of toolchains.

  • Device Manager – A unified interface for identifying, managing, and programming Silicon Labs hardware. It simplifies firmware flashing, serial communication, and board detection, supporting everything from bring-up to production.

  • Simplicity Commander – A command-line tool for programming, debugging, and security configuration. Engineers can erase, flash, or query devices, making it ideal for CI/CD and production automation.

  • Network Analyzer – A protocol-aware tracing tool for wireless traffic, offering real-time visibility into packet exchanges across Bluetooth LE, Zigbee, Thread, and Matter networks. Engineers can visualize events and diagnose performance issues efficiently.

  • Energy Profiler – A real-time power measurement tool that correlates energy consumption directly to code execution, helping developers minimize current draw in battery-powered designs.

  • Wireless Tools – A full suite of configuration, control/debug, and analysis tools for all wireless technologies, helping teams fine-tune wireless performance.

Each tool can function independently or as part of the complete Simplicity Ecosystem. Together, they deliver a modular workflow that simplifies setup, boosts productivity, and provides deep visibility into device behavior.

Evolving the Developer Experience with Simplicity AI SDK

Silicon Labs also revealed the Simplicity AI SDK, a framework that will extend the ecosystem’s developer-first design into an AI-augmented workflow enabling significant gains in innovation and productivity. The Simplicity AI SDK combines context awareness and intelligent automation to accelerate development. It augments the engineer by acting as a collaborator that interprets code, surfaces insights, and assists with tasks across the lifecycle—from project setup to field debugging.

The first release will integrate with VS Code to let developers “chat with their code.” It can explain functions, trace errors, and suggest improvements in real time, drawing on an understanding of project context and Silicon Labs SDKs. This collaboration between developers and intelligent tools marks a shift toward AI-assisted design where creativity and precision coexist.

At the heart of Simplicity AI SDK is dynamic context engineering, which gives AI agents the right data at the right time. This allows them to understand project structure, interpret documentation, and provide contextual support without manual lookup. Future updates will extend these capabilities across Silicon Labs’ tools, enabling adaptive debugging, optimization, and application generation.

A full exploration of the Simplicity AI SDK’s roadmap and philosophy is available in Silicon Labs Senior Vice President of Software Manish Kothari’s blog post, “Shaping the Future of IoT Development with Simplicity AI SDK“.

The Simplicity AI SDK will enter public access in 2026, beginning with developer feedback and beta testing.

Get Started with the Simplicity Ecosystem

Simplicity Studio 6 is available today for download at https://www.silabs.com/software-and-tools/simplicity-studio.

Public launch of the Simplicity AI SDK is planned for 2026. Join the Simplicity AI SDK early access waitlist to be among the first to receive updates.

About Silicon Labs

Silicon Labs (NASDAQ: SLAB) is the leading innovator in low-power wireless connectivity, building embedded technology that connects devices and improves lives. Merging cutting-edge technology into the world’s most highly integrated SoCs, Silicon Labs provides device makers with the solutions, support, and ecosystems needed to create advanced edge connectivity applications. Headquartered in Austin, Texas, Silicon Labs has operations in over 16 countries and is the trusted partner for innovative solutions in the smart home, industrial IoT, and smart cities markets. Learn more at www.silabs.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/silicon-labs-unveils-the-next-evolution-of-iot-development-with-the-simplicity-ecosystem-302590835.html

SOURCE Silicon Labs

Posted on

Adlai Nortye to Present Short Talk on AN4035 Preclinical Results at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 22, 2025 (GLOBE NEWSWIRE) — Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will deliver an oral presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held from October 22-26, 2025, in Boston, MA.

Key highlights of the presentation include:

  • AN4035 demonstrated strong intracellular payload retention, driving nanomolar to picomolar cytotoxicity in CEACAM5-positive/RAS-addicted cancer cell lines, along with a potent bystander-killing effect
  • AN4035 induced deep regression in CEACAM5-positive/RAS-addicted CDX and PDX models, achieving a 73% objective response rate in a patient-derived xenograft trial (N=26)
  • AN4035 exhibited a favorable preliminary toxicology profile in cynomolgus monkeys

Tricomplex pan-RAS(ON) inhibitors currently in clinical development have demonstrated encouraging efficacy; however, their therapeutic potential has been limited by presumably on-target, off-tumor toxicities, particularly in the skin and gastrointestinal tract. AN4035, Adlai Nortye’s novel CEACAM5-targeting antibody-drug conjugate (ADC), was specifically designed to address these limitations. By delivering a proprietary pan-RAS(ON) inhibitor payload directly to tumors, AN4035 aims to reduce systemic toxicities, widen the therapeutic window and enable rational combination therapies.

“We are delighted that AN4035, our first-in-class CEACAM5-targeting ADC armed with our proprietary pan-RAS(ON) inhibitor payload, has been selected for an oral presentation at this prestigious conference,” said Archie Tse, MD, PhD, Head of Research and Development at Adlai Nortye. “We hypothesized that an ADC approach could overcome some of the limitations of pan-RAS(ON) inhibitors by focusing their activity within tumors, thereby improving efficacy while minimizing on-target, off-tumor toxicities. The encouraging preclinical results we have seen to date support this hypothesis and reinforce our belief that AN4035 could represent the next generation of therapies against RAS-addicted tumors — either as stand-alone treatments or in rational combinations, especially for CEACAM5 overexpressing tumors such as colorectal cancer.”

This recognition underscores the strength of Adlai Nortye’s integrated ADC and small molecule discovery platforms and reflects the Company’s continued commitment to delivering transformative oncology therapies that expand the therapeutic window for patients with difficult-to-treat cancers.


Oral Presentation details:

Abstract title: Discovery of AN4035: A novel CEACAM5-targeting antibody drug conjugate (ADC) armed with a proprietary pan-RAS(ON) inhibitor payload, designed to broaden the therapeutic window (Abstract# LB-C001)

Date and Time: Saturday, October 25, 2025; 11:45 AM – 12:15 PM ET

Session Title: Spotlight on Proffered Papers 3: Novel Therapeutic Agents

Location: Level 3, Ballroom AB, Hynes Convention Center, Boston, MA


Poster Presentation details:

Poster Title: Discovery of AN4035: A novel CEACAM5-targeting antibody drug conjugate (ADC) armed with a proprietary pan-RAS(ON) inhibitor payload, designed to broaden the therapeutic window

Poster Session date and time: Saturday, October 25, 12:30 AM – 16:00 PM ET

Location: Poster Session C

Poster Number: LB-C001

For more information, please refer to the AACR website and conference app.

About AN4035

AN4035 is a proprietary CEACAM5-targeting antibody drug conjugate (ADC) designed to deliver potent anti-tumor activity with an improved therapeutic window. It is armed with Adlai Nortye’s first-in-class pan-RAS(ON) inhibitor payload, which effectively target a broad spectrum of CEACAM5-expressing, RAS-driven cancers.

About Adlai Nortye

Adlai Nortye (NASDAQ: ANL) is a global clinical-stage company focused on the development of innovative cancer therapies, with global R&D centers in the U.S. and China. We are advancing a portfolio of innovative drug candidates across two key therapeutic areas: next-generation PD-1/L1 modulation, including AN8025, a multifunctional fusion protein designed to modulate both T cells and antigen-presenting cells, and AN4005, a first-in-class oral small-molecule PD-L1 inhibitor; and RAS-targeted therapies, including AN9025, an oral pan-RAS(ON) inhibitor with potential to address multiple RAS-driven cancers, and AN4035, a novel CEACAM5-targeting antibody-drug conjugate armed with a potent pan-RAS(ON) inhibitor payload.

Forward-Looking Statement

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “potential,” “continue,” “ongoing,” “targets” and similar statements. Among other things, statements that are not historical facts, including statements about the Company’s beliefs and expectations, the business outlook and quotations from management in this announcement, as well as the Company’s strategic and operational plans, are or contain forward-looking statements.

The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve inherent risks and uncertainties. Factors that could cause the Company’s actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the initiation, timing, progress and results of the Company’s preclinical studies, clinical trials and other therapeutic candidate development efforts; the Company’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; whether the clinical trial results will be predictive of real-world results; the Company’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of the Company’s therapeutic candidates; the Company’s ability to establish, manage, and maintain corporate collaborations, as well as the ability of its collaborators to execute on their development and commercialization plans; the implementation of the Company’s business model and strategic plans for its business and therapeutic candidates; the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; estimates of the Company’s expenses, future revenues, capital requirements and its needs for and ability to access sufficient additional financing; risks related to changes in healthcare laws, rules and regulations in the PRC and United States or elsewhere. Further information regarding these and other risks is included in the Company’s filings with the SEC. All information provided in this announcement and in the attachments is as of the date of this announcement, and the Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Company contact:
Investor Relations
Email: [email protected]



Posted on

Viking Celebrates 100 Ships Around the World with Ceremony Naming Nine Newest River Ships Across Six Countries

Viking Celebrates 100 Ships Around the World with Ceremony Naming Nine Newest River Ships Across Six Countries

Historic Milestone Continues Viking’s History of Connecting Curious Travelers in Every Corner of the Globe

LOS ANGELES–(BUSINESS WIRE)–
Viking® (www.viking.com) (NYSE: VIK) today announced the naming of its nine newest river ships—including the company’s 100th ship—during a simultaneous ceremony in Basel, Switzerland. Of the nine new river ships, the Viking Annar, the Viking Dagur, the Viking Eldir and the Viking Honir will sail Viking’s most popular itineraries along the Rhine, Main and Danube rivers. The Viking Nerthus, the Viking Gyda and the Viking Tonle sail the Seine, Douro and Mekong rivers, respectively. The two other new ships named today—the Viking Thoth and the Viking Amun—sail the Nile River. The ceremony also marked a major milestone—Viking now has more than 100 ships across its award-winning river, ocean and expedition fleet, more than any other cruise line. This achievement reflects the company’s history of industry-leading innovations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021249797/en/

Viking today celebrated the naming of its nine newest river ships, including the company’s 100th ship during a ceremony in Basel, Switzerland. Pictured here, Viking Chairman and CEO Torstein Hagen, Executive Vice President of Product Karine Hagen, and the godparents and captains of the nine ships on board the new Viking Honir for the ceremony. For more information, visit www.viking.com.

Viking today celebrated the naming of its nine newest river ships, including the company’s 100th ship during a ceremony in Basel, Switzerland. Pictured here, Viking Chairman and CEO Torstein Hagen, Executive Vice President of Product Karine Hagen, and the godparents and captains of the nine ships on board the new Viking Honir for the ceremony. For more information, visit www.viking.com.

“Today we are proud to name our newest river ships and to honor the nine distinguished members of our extended Viking family serving as their godparents,” said Torstein Hagen, Chairman and CEO of Viking. “We have always been quite a bit different from others in the travel industry—we like to be contrarian. Over the last 28 years, we have grown from four ships to more than 100—a fleet size that no other line has achieved—and we have done so because of our innovative approach. First, we modernized river voyages; then we reinvented ocean voyages and perfected the expedition experience. We look forward to continuing our leadership in experiential travel in the years to come.”

Viking Naming Ceremony

For thousands of years, it has been an ancient maritime tradition for each new ship to have a ceremonial godmother. Viking has adapted this custom and, for its ships in Egypt, extended it to include godfathers. Viking’s tradition is to appoint individuals who have made an impact—either in the world, or in the life of Viking. For its nine newest river ships, the company invited colleagues and partners in the extended Viking family to serve as godparents, including:

  • Allison Becker, Senior Vice President, General Counsel, Viking—Godmother of the Viking Nerthus
  • Sara Conley, Senior Vice President of Brand, Creative and Communications, Viking—Godmother of the Viking Dagur
  • Chitra Goswami, Senior Vice President of Finance, Viking—Godmother of the Viking Gyda
  • Yumi Kim, Senior Vice President of Finance, Europe, Viking—Godmother of the Viking Eldir
  • Michelle Patterson, Senior Vice President, Corporate Controller, Viking—Godmother of the Viking Annar
  • Laura Perlman, Senior Vice President of Marketing Planning, International & Product, Viking—Godmother of the Viking Tonle
  • Michele Saegesser, Vice President, Trade Development and Training, Viking—Godmother of the Viking Honir
  • Youssef Fouad Amin, Chief Executive Officer & Chairman, Sherry Nile Cruises—Godfather of the Viking Thoth
  • Sherif El Banna, Chief Executive Officer, Cosmos Egypt—Godfather of the Viking Amun

The naming ceremony took place in Basel on board the Viking Honir and was connected virtually to the eight other new ships, which were located across five other countries around the world. The Viking Nerthus was in Paris, France; the Viking Dagur, the Viking Eldir and the Viking Annar were in Rostock, Germany; the Viking Gyda was in Porto, Portugal; the Viking Tonle was in Mỹ Tho, Vietnam; and the Viking Thoth and the Viking Amun were in Luxor, Egypt.

Guests at the naming event enjoyed performances by Sissel Kyrkjebø, one of the world’s leading crossover sopranos and godmother of the Viking Jupiter®; Norwegian violinist Tor Jaran Apold; the Viennese Residence Orchestra; and a Basel girls’ choir.

Viking’s Award-Winning Fleet

The naming of Viking’s newest river ships follows a string of recent accolades for the company. Viking was rated #1 for Oceans and #1 for Rivers by Condé Nast Traveler for the fifth year in a row in the 2025 Readers’ Choice Awards. Viking is also rated a “World’s Best” by Travel + Leisure—no other travel company has simultaneously received such honors by both publications. Viking was also recognized in U.S. News & World Report’s 2025 Best Cruise Lines rankings as Best Luxury Line, Best Line for Couples and Best Line in the Mediterranean for the fourth consecutive year. Viking’s ocean ships continue to be rated and “Recommended” as part of the Forbes Travel Guide Star Awards, an annual independent evaluation for luxury travel brands. Additionally, Viking received seven awards across its ocean, river and expedition categories in the Cruise Critic 2024 Best in Cruise Awards.

Media Assets

For more information about Viking, or for images and b-roll, please contact [email protected].

About Viking

Viking (NYSE: VIK) is a global leader in experiential travel with a fleet of more than 100 ships, exploring 21 rivers, five oceans and all seven continents. Designed for curious travelers with interests in science, history, culture and cuisine, Chairman and CEO Torstein Hagen often says Viking offers experiences For The Thinking Person™. Viking has more than 450 awards to its name, including being rated #1 for Rivers and #1 for Oceans five years in a row by Condé Nast Traveler in the 2025 Readers’ Choice Awards. Viking is also rated a “World’s Best” by Travel + Leisure—no other travel company has simultaneously received such honors by both publications. For additional information, contact Viking at 1-800-2-VIKING (1-800-284-5464) or visit www.viking.com.

Email: [email protected]

KEYWORDS: Portugal Southeast Asia Viet Nam United States Switzerland North America Asia Pacific Egypt Europe Africa Germany France California

INDUSTRY KEYWORDS: Other Consumer Maritime Transport Transportation Consumer Destinations Vacation Travel Cruise

MEDIA:

Photo
Photo
Viking today celebrated the naming of its nine newest river ships, including the company’s 100th ship during a ceremony in Basel, Switzerland. Pictured here, Viking Chairman and CEO Torstein Hagen, Executive Vice President of Product Karine Hagen, and the godparents and captains of the nine ships on board the new Viking Honir for the ceremony. For more information, visit www.viking.com.
Photo
Photo
The Viking Honir, one of the nine Viking river ships named as part of the company’s 100th ship milestone celebration, pictured on the Rhine River in Basel, Switzerland, during the naming ceremony. For more information, visit www.viking.com.
Photo
Photo
Pictured here, Karine Hagen and British photographer Alastair Miller preparing for the naming ceremony in Basel, Switzerland. For more information, visit www.viking.com.
Photo
Photo
Pictured here, Viking Chairman and CEO Torstein Hagen during a brief rain shower at the naming ceremony for its nine new river ships including the company’s 100th ship. For more information, visit www.viking.com.
Photo
Photo
Godparents and captains gathered on board the Viking Honir in Basel, Switzerland, for the naming ceremony of the company’s new river ships. Viking invited colleagues and partners from its extended family to serve as godparents for its nine newest river ships. For more information, visit www.viking.com.
Photo
Photo
Pictured here, Sissel Kyrkjebø, one of the world’s leading crossover sopranos and godmother of the Viking Jupiter performs with violinist Tor Jaran Apold and a Basel girls’ choir at the naming ceremony. For more information, visit www.viking.com.
Photo
Photo
Sissel Kyrkjebø, one of the world’s leading crossover sopranos and godmother of the Viking Jupiter, performing at the naming ceremony for Viking’s nine new river ships. For more information, visit www.viking.com.
Photo
Photo
Pictured here, Sissel Kyrkjebø, one of the world’s leading crossover sopranos and godmother of the Viking Jupiter, Norwegian violinist Tor Jaran Apold and a Basel girls’ choir performing at the naming ceremony. For more information, visit www.viking.com.
Photo
Photo
Kaspar Sutter, member of the Governing Council of the Canton of Basel-Stadt, speaks about Viking’s positive impact on tourism in Basel during the naming ceremony. For more information, visit www.viking.com.
Photo
Photo
Kaspar Sutter, member of the Governing Council of the Canton of Basel-Stadt, with Torstein Hagen, Chairman and CEO of Viking, at the naming ceremony in Basel, Switzerland. For more information, visit www.viking.com.
Photo
Photo
Torstein Hagen, Chairman and CEO of Viking, and Karine Hagen, Executive Vice President of Product, on board Viking Honir during the naming ceremony in Basel, Switzerland. For more information, visit www.viking.com.
Photo
Photo
Torstein Hagen, Chairman and CEO of Viking, extends his thanks to the captain of the Viking Thoth during the naming ceremony in Basel, Switzerland. For more information, visit www.viking.com.
Photo
Photo
Pictured here, a moment of unplanned fun between Sara Conley, godmother of the Viking Dagur, and the ship’s captain, at the naming of their ship during the ceremony. For more information, visit www.viking.com.
Photo
Photo
Pictured here, Laura Perlman, godmother of the Viking Tonle in Basel, Switzerland, as a monk offers a blessing for the ship via remote video from Mỹ Tho, Vietnam. For more information, visit www.viking.com.
Photo
Photo
Pictured here, all of the captains and godparents of Viking’s nine newest river ships with Viking Chairman and CEO Torstein Hagen, during the naming ceremony dinner in Basel, Switzerland. For more information, visit www.viking.com.
Logo
Logo
Posted on

Unity Powers Launch Titles for Samsung’s Galaxy XR and Accelerates the Android XR Ecosystem

Unity Powers Launch Titles for Samsung’s Galaxy XR and Accelerates the Android XR Ecosystem

Developers now have a production-ready path to bring immersive Unity experiences to Galaxy XR and the next wave of Android XR devices

SAN FRANCISCO–(BUSINESS WIRE)–Unity (NYSE: U), the leading platform to create and grow games and interactive experiences, today announced the general availability of Android XR support in Unity 6 — making it easy for developers to reach new audiences and platforms with their games and apps.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021117043/en/

Google Maps XR, built with Unity, brings the Immersive View feature to Android XR, allowing users to explore locations in detailed 3D environments.

Google Maps XR, built with Unity, brings the Immersive View feature to Android XR, allowing users to explore locations in detailed 3D environments.

“By collaborating closely with Google and Samsung, we integrated Android XR tools into Unity 6 early and verified them with developers in real production environments ahead of the launch,” said Alex Blum, COO at Unity. “We’re not just optimizing for one headset — we’re building for an open, scalable Android XR ecosystem where developers can reach new markets with less lift and more confidence.”

“Unity’s support of Android XR made it really easy for us to get started,” said Andrew Eiche, CEO of Owlchemy Labs. “We were able to bring some of our biggest games to Android XR in about a week, which helped us reach more players without a ton of extra work. That time savings also let us build something completely new with Inside [JOB].”

Unity’s day-one Android XR support opens the door for teams across gaming, education, entertainment, and enterprise industries to quickly build new games and apps or quickly port existing Unity ones to the Android XR ecosystem. Several launch-day experiences built with Unity are now available for Galaxy XR, including:

  • Google Maps XR (by Google): This new version of Google Maps brings the Immersive View feature to Android XR, allowing users to explore locations in detailed 3D environments. More information about how Google leveraged Unity to create Google Maps XR is available here.
  • NFL Pro Era (by StatusPRO Inc): The first licensed NFL virtual reality simulation game is now available on Android XR, alongside existing versions for Meta Quest, PlayStation VR, and Windows.
  • Inside [JOB] (by Owlchemy Labs): This new mixed-reality experience introduces users to Android XR interactions. Owlchemy also used Unity to bring its popular titles Vacation Simulator and Job Simulator to Android XR.

Unity’s Android XR support is available in Unity 6 and later versions, and is currently open to all developers.

About Unity

Unity [NYSE: U] offers a suite of tools to create, market, and grow games and interactive experiences across all major platforms from mobile, PC, and console, to extended reality. For more information, visit Unity.com.

Forward-looking statement

This publication contains “forward-looking statements,” as that term is defined under federal securities laws, including, in particular, statements about Unity’s plans, strategies, and objectives. The words “believe,” “may,” “will,” “estimate,” “continue,” “intend,” “expect,” “plan,” “project,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks, uncertainties, and assumptions. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. Further information on these and additional risks that could affect Unity’s results is included in our filings with the Securities and Exchange Commission (SEC) which are available on the Unity Investor Relations website. Statements herein speak only as of the date of this release, and Unity assumes no obligation to, and does not currently intend to, update any such forward-looking statements after the date of this publication except as required by law.

Unity PR Contact:

Adam Dalezman

[email protected]

KEYWORDS: California North America United States Ireland United Kingdom Europe

INDUSTRY KEYWORDS: Apps/Applications Mobile/Wireless Technology Electronic Games Entertainment Software Audio/Video Networks Internet Hardware

MEDIA:

Photo
Photo
Google Maps XR, built with Unity, brings the Immersive View feature to Android XR, allowing users to explore locations in detailed 3D environments.
Photo
Photo
Google Maps XR, built with Unity, brings the Immersive View feature to Android XR, allowing users to explore locations in detailed 3D environments.
Logo
Logo
Posted on

Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock

Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock

WALTHAM, Mass.–(BUSINESS WIRE)–
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today announced the pricing of an underwritten public offering of shares of its common stock. Viridian is selling a total of 11,425,000 shares of common stock at a public offering price of $22.00 per share. In addition, Viridian has granted the underwriters a 30-day option to purchase an additional 1,713,750 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to Viridian from the offering are expected to be approximately $251,350,000, before deducting underwriting discounts and commissions and offering expenses payable by Viridian and assuming no exercise of the underwriters’ option to purchase additional shares.

All of the shares to be sold in the underwritten public offering are being offered by Viridian. The offering is expected to close on or about October 23, 2025, subject to customary closing conditions.

Viridian intends to use the proceeds from the proposed underwritten public offering of its shares of common stock, together with its cash, cash equivalents and short-term investments, to fund the company’s commercial launch activities related to veligrotug and VRDN-003 and research and development activities, as well as for working capital and general corporate purposes.

Jefferies, Leerink Partners, Evercore ISI and Stifel are acting as joint book-running managers for the offering. Wedbush PacGrow is acting as co-manager for this offering.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission (SEC) and became effective on September 5, 2025. A final prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering will be filed with the SEC. The securities described above have not been qualified under any state blue sky laws. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. The offering will only be made by means of a prospectus, copies of which may be obtained at the SEC’s website at www.sec.gov, or by request to Jefferies LLC (Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022; telephone: 877-821-7388; email: [email protected]);Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525 ext. 6105, or by email at [email protected]; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, by telephone at (888) 474-0200 or by email at [email protected]; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, telephone: (415) 364‐2720 or by emailing [email protected].

About Viridian Therapeutics, Inc.

Viridian is a biopharmaceutical company focused on discovering, developing and commercializing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas.

Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting a pivotal program for veligrotug (VRDN-001), including two global phase 3 clinical trials (THRIVE and THRIVE-2), to evaluate its efficacy and safety in patients with active and chronic TED. Both THRIVE and THRIVE-2 reported positive topline data, meeting all the primary and secondary endpoints of each study. Viridian is also advancing VRDN-003 as a potential best-in-class subcutaneous therapy for the treatment of TED, including two ongoing global phase 3 pivotal clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients with active and chronic TED.

In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.

Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as, but not limited to, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or other similar terms or expressions that concern the company’s expectations, plans and intentions. Forward-looking statements include, without limitation, statements regarding: the underwritten public offering; the company’s expectations with respect to the use of the net proceeds from the underwritten public offering; the company’s plans regarding commercial launch activities related to veligrotug and VRDN-003 and research and development activities; the impact of a prolonged United States federal government shutdown; the company’s belief that VRDN-003 may be a best-in-class subcutaneous therapy for the treatment of TED; and the potential for the company’s novel portfolio of FcRn inhibitors to be developed in multiple autoimmune diseases. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on the company’s current beliefs, expectations and assumptions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to: the satisfaction of customary closing conditions related to the underwritten public offering; and other risks and uncertainties identified in the company’s filings with the SEC, including those risks set forth under the caption “Risk Factors” in the company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the SEC on August 6, 2025, and other subsequent disclosure documents filed with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither the company, nor its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date hereof.

Investor & Media Contact:

Greg Rossino

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Professional Services Health Finance Clinical Trials Pharmaceutical Optical Biotechnology

MEDIA:

Logo
Logo
Posted on

RAPT Therapeutics Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced the pricing of an underwritten public offering of 8,333,334 shares of its common stock at a price to the public of $30.00 per share. In addition, RAPT has granted the underwriters a 30-day option to purchase up to an additional 1,250,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being offered by RAPT. The gross proceeds from the offering to RAPT are expected to be approximately $250.0 million, before deducting underwriting discounts and commissions and other offering expenses, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about October 23, 2025, subject to customary closing conditions.

Leerink Partners, TD Cowen, Guggenheim Securities, Wells Fargo Securities and LifeSci Capital are acting as joint bookrunning managers for the offering. H.C. Wainwright & Co. and Clear Street are acting as lead managers for the offering.

The offering is being made pursuant to a shelf registration statement, including a base prospectus, filed by RAPT with the Securities and Exchange Commission (the “SEC”), which was declared effective by the SEC on August 17, 2023. The offering may be made only by means of a prospectus supplement and accompanying prospectus. A preliminary prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and is available on the SEC’s website at www.sec.gov. A final prospectus supplement and accompanying prospectus will be filed with the SEC. When available, electronic copies of the final prospectus supplement and the accompanying prospectus may also be obtained from: Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at 1-800-808-7525 ex. 6132 or by email at [email protected]; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at [email protected]; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at [email protected]; Wells Fargo Securities, LLC, Attention: Wells Fargo Securities, 90 South 7th Street, 5th Floor, Minneapolis, MN 55402, at 800-645-3751 (option #5) or email a request to [email protected]; or LifeSci Capital LLC at 1700 Broadway, 40th Floor, New York, New York 10019, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About RAPT Therapeutics, Inc.

RAPT is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases. Utilizing our deep and proprietary expertise in immunology, we develop novel therapies that are designed to modulate the critical immune responses underlying these diseases.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to RAPT’s expectations regarding the offering, including expected gross proceeds and anticipated closing date, the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. RAPT cautions investors not to place undue reliance on the forward-looking statements contained in this release. These risks and uncertainties include, without limitation, risks and uncertainties related to market conditions, the risk that the public offering will not be consummated on the terms or in the amounts contemplated or otherwise, and the satisfaction of customary closing conditions related to the public offering. Risks and uncertainties relating to RAPT and its business can be found in the “Risk Factors” section of RAPT’s Form 10-Q for the quarter ended June 30, 2025, filed with the SEC on August 7, 2025, and in the preliminary prospectus supplement related to the public offering filed with the SEC on October 21, 2025, and in the final prospectus supplement related to the public offering to be filed with the SEC. RAPT undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in RAPT’s expectations, except as required by law.

RAPT Investor Contact:

Sylvia Wheeler


[email protected]

RAPT Media Contact:

Aljanae Reynolds


[email protected]



Posted on

AST SpaceMobile Prices Repurchase of Convertible Senior Notes to be Funded By Concurrent Registered Direct Offering of Class A Common Stock

AST SpaceMobile Prices Repurchase of Convertible Senior Notes to be Funded By Concurrent Registered Direct Offering of Class A Common Stock

Repurchasing $50.0 million principal amount of existing convertible senior notes and removing approximately 1.85 million underlying shares as well as approximately $13.5 million of remaining interest

Issuing approximately 2.0 million shares to participating note holders to fund the repurchase

MIDLAND, Texas–(BUSINESS WIRE)–
AST SpaceMobile, Inc. (“AST SpaceMobile”) (NASDAQ: ASTS), the company building the first and only space-based cellular broadband network accessible directly by everyday smartphones, designed for both commercial and government applications, today announced the pricing of a cash repurchase (the “Repurchase”) of $50.0 million aggregate principal amount of its 4.25% convertible senior notes due 2032 (the “Existing Notes”) and its offering of approximately 2.0 million shares of its Class A common stock to holders of Existing Notes participating in the Repurchase in a direct placement registered under the Securities Act of 1933, as amended (the “Registered Direct Offering”).

With this series of transactions, AST SpaceMobile will issue approximately 0.2 million incremental shares to the underlying shares of the Existing Notes being repurchased while removing $50.0 million of debt from the balance sheet and approximately $13.5 million of remaining interest. Both the closing of the Repurchase and the Registered Direct Offering are expected to take place on or about October 29, 2025. The transactions are cross-conditional.

Repurchase of Existing Notes

AST SpaceMobile intends to use the net proceeds from the Registered Direct Offering, together with cash on hand, to repurchase $50.0 million principal amount of the Existing Notes for cash pursuant to separate, privately negotiated transactions with a limited number of holders of the Existing Notes. After giving effect to the Repurchase, $50.0 million aggregate principal amount of the Existing Notes will remain outstanding.

Based on the initial conversion rate of 37.0535 shares of Class A common stock per $1,000 principal amount of Existing Notes, which is subject to customary anti-dilution adjustment provisions, approximately 1.85 millionshares of Class A common stock underlying the repurchased Existing Notes will be unreserved after giving effect to the Repurchase and will be available for future issuance.

As part of the Repurchase, AST SpaceMobile did not terminate or amend the existing capped call transactions previously entered into in connection with the issuance of the Existing Notes, which will remain outstanding upon the completion of this transaction, but AST SpaceMobile may do so in the future. The existing capped call transactions are expected to reduce potential dilution and/or offset certain cash payments upon a conversion of Existing Notes.

In connection with the Repurchase, certain holders of the Existing Notes that participate in the Repurchase may purchase or sell shares of AST SpaceMobile’s Class A common stock in the open market or enter into or unwind various derivative transactions with respect to AST SpaceMobile’s Class A common stock to unwind any hedge positions they may have with respect to the Existing Notes or to hedge or unwind their exposure in connection with the Repurchase.

The amount of AST SpaceMobile’s Class A common stock to be sold or purchased by such holders or the notional number of shares of AST SpaceMobile’s Class A common stock underlying such derivative transactions may be substantial in relation to the historic average daily trading volume of AST SpaceMobile’s Class A common stock. These activities may adversely affect the trading price of AST SpaceMobile’s Class A common stock. AST SpaceMobile cannot predict the magnitude of such market activities or the overall effect they will have on the price of its Class A common stock.

Registered Direct Offering

AST SpaceMobile has agreed to sell an aggregate of approximately 2.0 million shares of its Class A common stock in the Registered Direct Offering at a price of $78.61 per share to holders of the Existing Notes for cash. AST SpaceMobile intends to use the net proceeds, together with cash on hand, from the Registered Direct Offering to repurchase $50.0 million principal amount of the Existing Notes for cash in the Repurchase described above.

The Registered Direct Offering is being made pursuant to an effective shelf registration statement on file with the Securities and Exchange Commission (the “SEC”). The Registered Direct Offering is being made only by means of a prospectus supplement and an accompanying prospectus. An electronic copy of the preliminary prospectus supplement, together with the accompanying prospectus, is available on the SEC’s website at www.sec.gov. Alternatively, copies of the preliminary prospectus supplement, together with the accompanying prospectus, and when available, the final prospectus supplement can be obtained by contacting: AST SpaceMobile, Inc., Midland International Air & Space Port, 2901 Enterprise Lane, Midland, Texas 79706, Attention: Secretary or (432) 276-3966.

UBS Investment Bank is acting as placement agent and financial advisor and ICR Capital LLC is acting as financial advisor for the placement.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any shares of AST SpaceMobile’s Class A common stock, nor will there be any sale of any of AST SpaceMobile’s securities in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful. This press release does not constitute an offer to buy, or a solicitation of any offer to sell, any Existing Notes.

Concurrent New Convertible Notes Offering

In a separate press release, AST SpaceMobile also announced today the pricing of its previously announced private offering of $1.0 billion aggregate principal amount of 2.00% convertible senior notes due 2036 (the “New Notes”). The size of the offering was increased from the previously announced $850.0 million principal amount of New Notes. AST SpaceMobile granted the initial purchasers an option to purchase, for settlement within a 13-day period beginning on, and including, the date on which the New Notes are first issued, up to an additional $150.0 million aggregate principal amount of New Notes. The issuance and sale of the New Notes are scheduled to settle on October 24, 2025, subject to customary closing conditions.

The completion of the Registered Direct Offering and the Repurchase is not contingent on the completion of the offering of the New Notes and the completion of the offering of New Notes is not contingent on the completion of the Registered Direct Offering and the Repurchase. The Registered Direct Offering and the Repurchase are cross-conditional. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any New Notes or shares of AST SpaceMobile’s Class A common stock, if any, issuable upon conversion of the New Notes.

About AST SpaceMobile

AST SpaceMobile is building the first and only global cellular broadband network in space to operate directly with standard, unmodified mobile devices and designed for both commercial and government applications. Our engineers and space scientists are on a mission to eliminate the connectivity gaps faced by today’s five billion mobile subscribers and finally bring broadband to the billions who remain unconnected.

Forward-Looking Statements

This communication contains “forward-looking statements” that are not historical facts, including statements concerning the completion of the Registered Direct Offering, the Repurchase and the offering of New Notes, the expected use of the net proceeds from the Registered Direct Offering and the potential impact of AST SpaceMobile’s anticipated repurchase of the Existing Notes and the completion, timing and size of the offering of New Notes. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes,” “expects,” “intends,” “may,” “will,” or, in each case, their negative or other variations or comparable terminology. These forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Such risks include, but are not limited to, whether AST SpaceMobile will consummate the Registered Direct Offering or the Repurchase, prevailing market conditions, the anticipated principal amount of the Existing Notes that will be repurchased in separately negotiated transactions with a limited number of holders of such notes, the anticipated use of the net proceeds from the Registered Direct Offering, whether AST SpaceMobile will consummate the offering of New Notes and the impact of general economic, industry or political conditions in the United States or internationally.

AST SpaceMobile cautions that the foregoing list of factors is not exclusive. AST SpaceMobile cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the Risk Factors in AST SpaceMobile’s Form 10-K for the fiscal year ended December 31, 2024 filed with the SEC on March 3, 2025, its Form 10-Q for the fiscal quarter ended March 31, 2025 filed with the SEC on May 12, 2025, its Form 10-Q for the fiscal quarter ended June 30, 2025 filed with the SEC on August 11, 2025, as amended on September 12, 2025, and the future reports that it may file from time to time with the SEC. AST SpaceMobile’s securities filings can be accessed on the EDGAR section of the SEC’s website at www.sec.gov. Except as expressly required by applicable securities law, AST SpaceMobile disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Investor Contact:

Scott Wisniewski

[email protected]

Media Contact:

Allison

Eva Murphy Ryan

917-547-7289

[email protected]

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Telecommunications Satellite Finance Professional Services Technology Aerospace Manufacturing Mobile/Wireless

MEDIA:

Logo
Logo
Posted on

AST SpaceMobile Announces Pricing of Private Offering of $1.0 Billion of Convertible Senior Notes Due 2036

AST SpaceMobile Announces Pricing of Private Offering of $1.0 Billion of Convertible Senior Notes Due 2036

MIDLAND, Texas–(BUSINESS WIRE)–
AST SpaceMobile, Inc. (“AST SpaceMobile”) (NASDAQ: ASTS), the company building the first and only space-based cellular broadband network accessible directly by everyday smartphones, designed for both commercial and government applications, today announced the pricing of $1.0 billion aggregate principal amount of convertible senior notes due 2036 (the “Notes”) in a private offering (the “Notes Offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The size of the offering has been increased from the previously announced $850.0 million principal amount of Notes. The sale of the Notes to the initial purchasers is expected to settle on October 24, 2025, subject to customary closing conditions.

The Notes have an initial conversion price of approximately $96.30 per share of AST SpaceMobile’s Class A common stock, which represents a premium of approximately 22.5% to the last reported sale price of AST SpaceMobile’s Class A common stock on October 21, 2025.

Option to Purchase Additional Notes:

AST SpaceMobile also granted the initial purchasers of the Notes in the Notes Offering an option to purchase, for settlement within a 13-day period beginning on, and including, the date on which the Notes are first issued, up to an additional $150.0 million aggregate principal amount of Notes.

Use of Proceeds:

AST SpaceMobile estimates that the net proceeds from the Notes Offering will be approximately $981.9 million (or approximately $1,129.2 million if the initial purchasers’ option to purchase additional Notes is exercised in full), after deducting the initial purchasers’ discounts and commissions and estimated offering expenses payable by AST SpaceMobile. AST SpaceMobile intends to use the net proceeds from the Notes Offering for general corporate purposes, including without limitation funding the deployment of AST SpaceMobile’s worldwide constellation of satellites in anticipation of adding incremental strategic markets for AST SpaceMobile’s SpaceMobile Service.

Additional Details of the Notes:

The Notes will be senior, unsecured obligations of AST SpaceMobile. The Notes will accrue interest at an annual rate of 2.00%, payable semiannually in arrears on January 15 and July 15 of each year, beginning on July 15, 2026. The Notes will mature on January 15, 2036, unless earlier converted, redeemed or repurchased.

Prior to the close of business on the business day immediately preceding October 15, 2035, noteholders will have the right to convert their Notes only upon the satisfaction of specified conditions and during certain periods. On or after October 15, 2035 and until the close of business on the second scheduled trading day immediately preceding January 15, 2036, noteholders may convert their Notes at any time regardless of these conditions. The initial conversion rate will be 10.3845 shares of AST SpaceMobile’s Class A common stock per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $96.30 per share of AST SpaceMobile’s Class A common stock, which represents a premium of approximately 22.5% over the last reported sale price of $78.61 per share of AST SpaceMobile’s Class A common stock on the Nasdaq Global Select Market on October 21, 2025), subject to adjustment in certain circumstances. AST SpaceMobile will settle conversions of Notes by paying or delivering, as the case may be, cash, shares of AST SpaceMobile’s Class A common stock, or a combination thereof, at AST SpaceMobile’s election.

The Notes will not be redeemable at AST SpaceMobile’s option prior to January 22, 2029. AST SpaceMobile may, at its option, redeem all or any portion of the Notes for cash on or after January 22, 2029, but only if the last reported sale price per share of AST SpaceMobile’s Class A common stock equals or exceeds 130% of the conversion price for a specified period of time and certain liquidity conditions have been satisfied. The redemption price will be equal to the principal amount of the Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date.

Noteholders will have the right, subject to certain conditions and exceptions described in the indenture governing the Notes (the “indenture”), to require AST SpaceMobile to repurchase for cash all or a portion of their Notes upon the occurrence of a fundamental change (as defined in the indenture) at a purchase price of 100% of their principal amount plus accrued and unpaid interest, if any, to, but excluding, the relevant repurchase date. In addition, following certain corporate events that occur prior to January 15, 2036 or if AST SpaceMobile delivers a notice of redemption, AST SpaceMobile will, in certain circumstances, increase the conversion rate for a noteholder who elects to convert its Notes in connection with such corporate events or convert its Notes in connection with such notice of redemption, as the case may be.

The Notes are only being offered and will only be sold to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A promulgated under the Securities Act by means of a private offering memorandum. Neither the Notes nor the shares of AST SpaceMobile’s Class A common stock potentially issuable upon conversion of the Notes, if any, have been, or will be, registered under the Securities Act or the securities laws of any other jurisdiction, and unless so registered, may not be offered or sold in the United States, except pursuant to an applicable exemption from, or in a transaction not subject to, such registration requirements.

This announcement is neither an offer to sell nor a solicitation of an offer to buy any of the Notes or any shares of AST SpaceMobile’s Class A common stock potentially issuable upon conversion of the Notes and shall not constitute an offer, solicitation, or sale in any jurisdiction in which such offer, solicitation, or sale is unlawful.

Registered Direct Offering/Existing Convertible Notes Repurchases:

In a separate press release, AST SpaceMobile also announced today the pricing of its previously announced registered direct offering of approximately 2.0 million shares of its Class A common stock, at a price of $78.61 per share. The issuance and sale of the shares of AST SpaceMobile’s Class A common stock are scheduled to settle on October 29, 2025, subject to customary closing conditions.

AST SpaceMobile intends to use the net proceeds from the registered direct offering, together with cash on hand, to repurchase $50.0 million aggregate principal amount of its existing 4.25% convertible senior notes due 2032 (the “Existing Notes”) in the existing convertible notes repurchases described below.

Concurrently with the pricing of the Notes Offering, AST SpaceMobile entered into separate, privately negotiated transactions with a limited number of holders of its Existing Notes to repurchase $50.0 million principal amount of the Existing Notes for cash (the “existing convertible notes repurchases”). The existing convertible notes repurchases will be subject to closing conditions that may not be consummated. In addition, following completion of the Notes Offering, AST SpaceMobile may repurchase additional existing notes.

In connection with the existing convertible notes repurchases, certain holders of the Existing Notes that participate in such repurchases may purchase or sell shares of AST SpaceMobile’s Class A common stock in the open market or enter into or unwind various derivative transactions with respect to AST SpaceMobile’s Class A common stock to unwind any hedge positions they may have with respect to the Existing Notes or to hedge or unwind their exposure in connection with such repurchases. The amount of AST SpaceMobile’s Class A common stock to be sold or purchased by such holders or the notional number of shares of AST SpaceMobile’s Class A common stock underlying such derivative transactions may be substantial in relation to the historic average daily trading volume of AST SpaceMobile’s Class A common stock. These activities may adversely affect the trading price of AST SpaceMobile’s Class A common stock and the trading price of the Notes and Existing Notes. AST SpaceMobile cannot predict the magnitude of such market activities or the overall effect they will have on the price of the Notes, the Existing Notes or AST SpaceMobile’s Class A common stock.

The completion of the Notes Offering is not contingent on the completion of the registered direct offering and the existing convertible notes repurchases and the completion of the registered direct offering and the existing convertible notes repurchases is not contingent on the completion of the Notes Offering. The registered direct offering and the existing convertible notes repurchases are cross-conditional. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any shares of AST SpaceMobile’s Class A common stock in the registered direct offering. This press release does not constitute an offer to buy, or a solicitation of any offer to sell, any Existing Notes.

About AST SpaceMobile

AST SpaceMobile is building the first and only global cellular broadband network in space to operate directly with standard, unmodified mobile devices and designed for both commercial and government applications. Our engineers and space scientists are on a mission to eliminate the connectivity gaps faced by today’s five billion mobile subscribers and finally bring broadband to the billions who remain unconnected.

Forward-Looking Statements

This communication contains “forward-looking statements” that are not historical facts, including statements concerning the completion of the Notes Offering, the granting of a 13-day option to purchase additional Notes, the expected use of the net proceeds from the Notes Offering, and the concurrent registered direct offering of AST SpaceMobile’s Class A common stock and separate repurchase of a portion of its Existing Notes. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes,” “anticipates,” “expects,” “intends,” “may,” “will,” “potential,” or, in each case, their negative or other variations or comparable terminology. These forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Such risks include, but are not limited to, whether AST SpaceMobile will consummate the Notes Offering, the registered direct offering and the existing convertible notes repurchase, prevailing market conditions, the anticipated principal amount of the Notes, which could differ based upon the exercise of the initial purchasers’ option to purchase additional Notes, the anticipated use of the net proceeds from the Notes Offering, which could change as a result of market conditions or for other reasons, whether AST SpaceMobile will consummate the registered direct offering or repurchase of Existing Notes, the effects of entering into these transactions, and the impact of general economic, industry or political conditions in the United States or internationally.

AST SpaceMobile cautions that the foregoing list of factors is not exclusive. AST SpaceMobile cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the Risk Factors in AST SpaceMobile’s Form 10-K for the fiscal year ended December 31, 2024 filed with the SEC on March 3, 2025, its Form 10-Q for the fiscal quarter ended March 31, 2025 filed with the SEC on May 12, 2025, its Form 10-Q for the fiscal quarter ended June 30, 2025 filed with the SEC on August 11, 2025, as amended on September 12, 2025, and the future reports that it may file from time to time with the SEC. AST SpaceMobile’s securities filings can be accessed on the EDGAR section of the SEC’s website at www.sec.gov. Except as expressly required by applicable securities law, AST SpaceMobile disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Investor Contact:

Scott Wisniewski

[email protected]

Media Contacts:

Allison

Eva Murphy Ryan

917-547-7289

[email protected]

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Telecommunications Satellite Networks Internet Technology Aerospace Manufacturing Mobile/Wireless

MEDIA:

Logo
Logo